Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of JYP0322 versus crizotinib in ROS1-positive advanced or metastatic non-small cell lung cancer
CTR20263480Phase 3Active
- Sponsor
- Guangzhou JOYO Pharma
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of JYP0322 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Guangzhou JOYO Pharma. Primary endpoint: Progression-free survival by BIRC. Started Sep 2026; status: active.
02
Drugs
JYP0322
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263480.